CONFERENCE GRANT--COMBINED MODALITY THERAPY

此应用程序请求对会议的部分支持 癌症的形态治疗“将于9月在弗吉尼亚州威廉斯堡举行 29日、30日和1986年10月1日。应用程序的具体请求是 会议教职员工、特邀演讲者和诺斯的差旅费用 美国初级调查员。这次会议的目的是 评价综合治疗的研究现状， 尤其是放射和化疗。上一次会议致力于 这个话题是在1978年提出的，现在已经有了大量的新信息 从那以后。具有不同的基本原理和协议设计、组合模式 治疗方法现已应用于多种肿瘤的临床治疗。这 会议将探讨联合使用的最佳方法 实验室和临床上的形态治疗。一个主要目标是 严格审查动物和人类肿瘤和正常组织模型，并 看看它们在预测临床结果方面是否有用。其他主题 将包括：药物和辐射耐药性，药物与辐射的相互作用， 减少急性和晚期发病率，以及辅助治疗。临床部 纳入的试验将限于第二阶段和随机第三阶段。 明确涉及特定组合情态概念的研究。 这次会议将是一次国际会议，它将把 参与组合模式研究的科学家和临床医生。这个 组织和计划委员会由16名具有专业知识的个人组成 在基础科学以及放射、内科和外科肿瘤学方面。这个 交流信息，这将包括在会议程序中， 应该为进一步的调查制定新的指导方针。六个人中的每一个 半天的会议将有一位主讲人和一位主席。这个 主旨演讲者将总结当前最先进的特定 主题和概述当前将在会议上讨论的问题。这个 会议主席将领导一小时的讨论，并将提供帮助 协调和编辑会议记录。信息交流将 主要是通过海报，每个作者有两分钟的时间 迷你幻灯片演示文稿的时段。

This application requests partial support for the conference "Combined Modality Therapy of Cancer" to be held in Williamsburg, Virginia, September 29, 30 and October 1, 1986. The specific request of the application is for the cost of travel for the conference faculty, invited speakers, and North American Junior investigators. The purpose of the conference is to evaluate the current status of combined modality therapy research, particularly radiation and chemotherapy. The last meeting dedicated to this topic was in 1978 and a great deal of new information is available since then. With varying rationales and protocol design, combined modality therapy is now in clinical use for a wide variety of tumors. This conference will explore the optimal approach to the use of combined modality therapy in the laboratory and the clinic. A major goal is to critically review animal and human tumor and normal tissue models, and to see if they are useful in predicting clinical outcome. Additional topics will include: drug and radiation resistance, drug-radiation interaction, decreasing acute and late morbidity, and adjuvant therapy. The clinical trials to be included will be limited to phase II and randomized phase III studies that clearly address specific combined modality concepts. The conference will be an international meeting tha will bring together scientists and clinicians involved in combined modality research. The organizing and program committee consists of 16 individuals with expertise in the basic sciences and in radiation, medical and surgical oncology. The exchange of information, which will be included in a meeting proceedings, should lead to new guidelines for further investigation. Each of the six half-day sessions will have a keynote speaker and a chairperson. The keynote speaker will summarize the current state-of-the-art of the specific topic and outline current probelms to be discussed in the session. The session chairperson will lead the one hour discussion period and will help coordinate and edit the meeting proceedings. The information exchange will be predominately through posters, with each author having a two minute period for a mini-slide presentation.